Enhancement of MAVS UFMylation and inhibition of lysosomal degradation of MAVS aggregates: New findings on broad-spectrum antiviral mechanism of Anemoside B4
- 2 June 2025
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 239, 117020
Abstract
No abstract availableKeywords
Funding Information
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Soochow University (YXY2304070)
- Soochow University
- National Natural Science Foundation of China (81903896, 82341087)
This publication has 56 references indexed in Scilit:
- The emerging roles of UFMylation in the modulation of immune responsesClinical and Translational Medicine, 2024
- E3 ubiquitin ligase ANKIB1 attenuates antiviral immune responses by promoting K48-linked polyubiquitination of MAVSCell Reports, 2024
- Anemoside B4, a new pyruvate carboxylase inhibitor, alleviates colitis by reprogramming macrophage functionInflammation Research, 2023
- Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activationJournal of Hepatology, 2023
- Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infectionJournal of Hepatology, 2022
- Anemoside B4 protects against IgE-dependent allergic responses by suppressing the PLC/IP3 and JAK/STAT3 pathwaysChemico-Biological Interactions, 2022
- COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese MedicineVirologica Sinica, 2020
- Regulation of MAVS activation through post-translational modificationsCurrent Opinion in Immunology, 2018
- Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: Evaluation of antiviral efficacy in a murine infection modelAntiviral Research, 2013
- MAVS Forms Functional Prion-like Aggregates to Activate and Propagate Antiviral Innate Immune ResponseCell, 2011